— in expenses

Advocacy: biotechnology innovation organization (BIO)'s advocacy efforts reflect the priorities identified by the BIO board of directors and the three section governing boards.the board of directors focuses on issues of importance to all BIO members, regardless of their size or technology. These cross-cutting advocacy accomplishments for the year are listed below: - safeguarded and advanced intellectual property protections, domestically and internationally.- fostered a dialogue about proactively advancing the socially responsible use of biotechnology.- promoted investment in government and academic research.- expanded outreach to foreign governments and international entities to educate on policy issues of importance to the biotechnology industry and to improve the investment and regulatory climate for biotech products.the health section advocacy accomplishments: - promoted healthcare policies that recognize both the promise and value of innovation.- advocated for a safe and predictable regulatory environment for value-based payment arrangements for drugs and biologics.- enhanced and protected patient access to innovative therapies and promoted the need for greater nondiscrimination enforcement against insurance benefit designs.- advocated for biosimilars policies that protect patient safety, promote biomedical innovation, and advance the science-based review and approval of biosimilars and interchangeable biological products.- promoted the value of u.s. Government investments in programs that improve access to immunizations and foster vaccine innovation, strengthened our ability to respond to bioterror threats or emerging infectious diseases, and encouraged development of new products to fight antimicrobial resistance (amr).- influenced improvements to the international environment for biomedical innovation and global public health preparedness.- advocated for the modernization of the clinical development paradigm.the emerging companies section advocacy accomplishments: - advanced the interest of emerging companies in capital formation and financial services policy.- advocated for fiscal policies supporting innovative emerging companies and investment in groundbreaking r&d; enhanced the voice of pre-revenue, r&d-intensive businesses- advocated for the removal of burdensome financial reporting regulations on emerging companies.the agriculture & environment section advocacy accomplishments:BIO's agriculture & environment (or ag & environment) section focuses on issues related to the organization's prior food & agriculture and industrial & environment sections. These include:- advocating on initiatives that strengthen the bioeconomy; and- meeting shared goals related to societal challenges such as food security, national security and climate change.the ag & environment section advocates and coordinates directly with government and industry stakeholders to increase the understanding and acceptance of biotech innovation, while also improving the regulatory and approval processes. This section promotes appropriate initiatives that support innovation, market access, and market acceptance.

— in expenses

Services: BIO's services include conferences and activities that bring advocacy accomplishments listed below:- safeguarded and advanced intellectual property protections, domestically and internationally.- fostered a dialogue about proactively advancing the socially responsible use of biotechnology.- promoted investment in government and academic research.- brought together industry stakeholders and investors for events ranging from the BIO international convention to conferences for business development executives.the BIO international convention attracts the most influential biotech and pharma attendees from 69 countries and 50 u.s. States, as well as the district of columbia and puerto rico and offers professional and business development opportunities. The net income from the convention supports our advocacy, public outreach, and other member service activities.the key elements of the BIO international convention are educational programming, exhibition, the BIO business forum, and networking events. These elements provide an opportunity for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to learn about recent scientific and policy developments, and schedule one-on-one meetings to discuss potential business opportunities. The BIO business forum at the convention hosts tens of thousands of partnering meetings among a few thousand companies, along with a couple hundred company presentations. The convention hosts hundreds of speakers, and over a thousand exhibitions with international, regional and state pavilions (and a number of product focus zones).beyond the convention, BIO hosts or co-hosts a number of national and international conferences that provide venues for member and non-member companies to present new data, meet with fellow biotech companies, and attract funding from investors and other organizations.